p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis.

Publication Type:

Journal Article


Oncogene, Volume 27, Issue 22, p.3145-55 (2008)


2008, 9,10-Dimethyl-1,2-benzanthracene, Animals, B-Lymphocytes, Carcinoma, Squamous Cell, Cell Proliferation, Center-Authored Paper, Chemotaxis, Leukocyte, Comparative Medicine Core Facility, Cyclin-Dependent Kinase Inhibitor p16, Human Biology Division, Lymph Nodes, Lymphangiogenesis, Lymphatic Metastasis, Macrophages, MICE, Mice, Transgenic, Neovascularization, Pathologic, Shared Resources, Skin Neoplasms, Tetradecanoylphorbol Acetate, Translational Bioimaging Center Core Facility, Tumor Suppressor Protein p53, Vascular Endothelial Growth Factor A


The ability of tumor cells to metastasize is increasingly viewed as an interaction between the primary tumor and host tissues. Deletion of the p19/Arf or p53 tumor suppressor genes accelerates malignant progression and metastatic spread of 7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced squamous cell carcinomas, providing a model system to address mechanisms of metastasis. Here, we show that benign pre-metastatic papillomas from wild-type mice trigger lymphangiogenesis within draining lymph nodes, whereas there is no growth of primary tumor lymphatic vessels. Lymph node lymphangiogenesis is greatly accelerated in papilloma-bearing p19/Arf- or p53-deficient mice, which coincides with the greater propensity of these tumors to progress to carcinomas and to metastasize. The extent of accumulation of B cells within the tumor-draining lymph nodes of wild-type mice predicted the level of lymph node lymphangiogenesis and metastatic potential. Arf or p53 deficiency strongly accelerated lymph node immune cell accumulation, in a manner that was associated with the extent of lymph node lymphatic sinus growth. This immune cell accumulation and lymph node lymphangiogenesis phenotype identifies host anti-tumor responses that could drive metastatic spread of cancers via the lymphatics.